Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndromeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether the gastrointestinal microbiome and peripheral immune signaling are associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Researchers combined rigorous clinical characterization with fecal bacterial metagenomics and plasma immune molecule analyses. They specifically looked at whether irritable bowel syndrome (IBS) co-morbidity and body mass index shaped bacterial composition and bacterial metabolic pathways.
Who was studied?
The study included 50 patients diagnosed with ME/CFS and 50 healthy controls. Controls were frequency-matched to patients for age, sex, race/ethnicity, geographic site, and season of sampling. This matched case-control design allowed comparisons of fecal and plasma profiles between the two groups.
What were the most important findings?
Topological analysis linked IBS co-morbidity, body mass index, fecal bacterial composition, and bacterial metabolic pathways, but found no such association with plasma immune molecules. IBS co-morbidity was the strongest factor separating topological networks based on bacterial profiles and metabolic pathways. Predictive selection models confirmed that ME/CFS subgroups defined by IBS status could be distinguished from controls with high accuracy, and the bacterial taxa predictive of ME/CFS with IBS differed from those predictive of ME/CFS without IBS.
What are the greatest implications of this study?
The findings suggest ME/CFS is not a single uniform condition but includes at least two microbiome-linked subgroups defined by IBS status. Fecal bacterial profiles and metabolic pathways, rather than circulating immune molecules, appear to track most closely with this clinical subdivision. This supports stratifying ME/CFS patients by gut comorbidity status when investigating mechanisms or designing future microbiome-targeted studies.